Experienced in Hydronephrosis

Fabio L. Cury

Montreal, QC, CA 
Experienced in Hydronephrosis
Montreal, QC, CA 
OverviewLocationsClinical Research

Overview

Fabio Cury practices in Montreal, Canada. Mr. Cury is rated as an Experienced expert by MediFind in the treatment of Hydronephrosis. His top areas of expertise are Muscle Invasive Bladder Cancer, Prostate Cancer, Bladder Cancer, Adult Soft Tissue Sarcoma, and Cystectomy.

His clinical research consists of co-authoring 79 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Hydronephrosis.

Gender
Male

Locations

Montreal, QC, Canada
Other Locations
Montreal, Canada
Quebec, QC, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
Enrollment Status: Active_not_recruiting
Publish Date: November 07, 2025
Intervention Type: Other, Radiation, Drug
Study Drug: Apalutamide
Study Phase: Phase 2
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Enrollment Status: Active_not_recruiting
Publish Date: October 28, 2025
Intervention Type: Radiation
Study Phase: Phase 3
Short Course Pre-operative RadiothErapy for Soft Tissue SarcOmas - a Phase I/II Trial (PRESTO)
Short Course Pre-operative RadiothErapy for Soft Tissue SarcOmas - a Phase I/II Trial (PRESTO)
Enrollment Status: Active_not_recruiting
Publish Date: June 25, 2025
Intervention Type: Radiation
Study Phase: Not Applicable
PSMA PET/CT Guided Intensification of Therapy in Patients at Risk of Advanced Prostate Cancer
PSMA PET/CT Guided Intensification of Therapy in Patients at Risk of Advanced Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 13, 2025
Intervention Type: Other, Diagnostic test
Study Phase: Phase 3
The Role of Stereotactic Body Radiotherapy in the Management of Castration-Resistant Prostate Cancer with Oligometastases: an Adaptive Phase II/III Randomized Trial.
The Role of Stereotactic Body Radiotherapy in the Management of Castration-Resistant Prostate Cancer with Oligometastases: an Adaptive Phase II/III Randomized Trial.
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2024
Intervention Type: Drug, Radiation
Study Drugs: Leuprolide acetate, Goserelin acetate, Triptorelin, Enzalutamide
Study Phase: Phase 2/Phase 3
A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The Prime Study
A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The Prime Study
Enrollment Status: Terminated
Publish Date: October 04, 2024
Intervention Type: Drug
Study Drug: Metformin
Study Phase: Phase 3
A Phase II, Multi-Centre Study, of Stereotactic Radiotherapy for Oligo-Progression in Metastatic Renal Cell Cancer Patients Receiving 1st Line Sunitinib Therapy
A Phase II, Multi-Centre Study, of Stereotactic Radiotherapy for Oligo-Progression in Metastatic Renal Cell Cancer Patients Receiving 1st Line Sunitinib Therapy
Enrollment Status: Completed
Publish Date: March 23, 2021
Intervention Type: Radiation
Study Phase: Phase 2
View 6 Less Clinical Trials

79 Total Publications

Reply by Authors.
Reply by Authors.
Journal: The Journal of urology
Published: September 10, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Cury's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile